ArticleInternational journal of hematology2022

Clinical impacts of frailty, poor performance status, and advanced age in carfilzomib-containing treatment for relapsed/refractory multiple myeloma: post hoc investigation of the KOTOSG multicenter pilot prospective observational study.

Yuka Kawaji-Kanayama et al.PubMed ↗Publisher ↗

No numbers read from the abstract.